Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STANDARD BIOTOOLS INC. Director's Dealing 2023

May 20, 2023

32853_dirs_2023-05-19_3b0e51c1-ee9c-4a6b-9902-d8c0526a38b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2023-05-17

Reporting Person: Casdin Eli (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-17 Common Stock P 250000 $1.8862 Acquired 250000 Indirect
2023-05-18 Common Stock P 150000 $2.1591 Acquired 400000 Indirect
2023-05-19 Common Stock P 800000 $2.2949 Acquired 1200000 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 46766 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.